RxDoctor Payments DataLook up a doctor →

Brian Benson, DPM

Foot & Ankle Surgery · Leesville, LANPI 1104350883

Payments from drug & device makers

$287,474in general payments, 2019–2025

Across 304 payments — averaging $945.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bone Support Inc.$99K
  • Medshape, Inc.$48K
  • Fusion Orthopedics USA, LLC$38K
  • New Standard Device, LLC Dba Metalogix$27K
  • Linvatec Corporation$22K
  • Nvision Biomedical Technologies, Inc.$10K
  • plus $44K from 28 others
$18,225in research payments, 2019–2025

Across 2 payments — averaging $9112.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acera Surgical, Inc.$18K

What the payments were for

  • Royalty or licence$1,2260%
  • Consulting fees$220,72679%
  • Speaking & faculty fees$5,2082%
  • Travel & lodging$39,84314%
  • Food & beverage$6,8792%
  • Education$3,0171%
  • Other$1,4901%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$287,474 in reported general payments places this provider in the 95th percentile of 92 foot & ankle surgery providers in Louisiana.

See all foot & ankle surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$2,711,599
Medicare patients
196
Services billed
3,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ammonium Lactate35$665
Ciclopirox16$305
Terbinafine Hcl31$235
Clotrimazole25$219
Gabapentin17$208
Doxycycline Hyclate16$181
Meloxicam39$117
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim14$76
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$58

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Leesville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →